Bristol-Myers Squibb Beheer

Beheer criteriumcontroles 3/4

De CEO Bristol-Myers Squibb is Chris Boerner, benoemd in Nov2023, heeft een ambtstermijn van 2.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 18.79M, bestaande uit 8.2% salaris en 91.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.006% van de aandelen van het bedrijf, ter waarde $ 6.23M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.2 jaar en 5.3 jaar.

Belangrijke informatie

Chris Boerner

Algemeen directeur

US$18.8m

Totale compensatie

Percentage CEO-salaris	8.18%
Dienstverband CEO	2.1yrs
Eigendom CEO	0.006%
Management gemiddelde ambtstermijn	2.2yrs
Gemiddelde ambtstermijn bestuur	5.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Chris Boerner's beloning veranderd ten opzichte van Bristol-Myers Squibb's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2025	n/a	n/a	US$6b
Jun 30 2025	n/a	n/a	US$5b
Mar 31 2025	n/a	n/a	US$5b
Dec 31 2024	US$19m	US$2m	-US$9b
Sep 30 2024	n/a	n/a	-US$7b
Jun 30 2024	n/a	n/a	-US$7b
Mar 31 2024	n/a	n/a	-US$6b
Dec 31 2023	US$8m	US$1m	US$8b
Sep 30 2023	n/a	n/a	US$8b
Jun 30 2023	n/a	n/a	US$8b
Mar 31 2023	n/a	n/a	US$7b
Dec 31 2022	US$7m	US$1m	US$6b
Sep 30 2022	n/a	n/a	US$7b
Jun 30 2022	n/a	n/a	US$7b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$7m	US$1m	US$7b
Sep 30 2021	n/a	n/a	-US$5b
Jun 30 2021	n/a	n/a	-US$5b
Mar 31 2021	n/a	n/a	-US$6b
Dec 31 2020	US$6m	US$953k	-US$9b
Sep 30 2020	n/a	n/a	-US$44m
Jun 30 2020	n/a	n/a	-US$563m
Mar 31 2020	n/a	n/a	US$954m
Dec 31 2019	US$6m	US$891k	US$3b

Compensatie versus markt: De totale vergoeding ($USD 18.79M ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 6.47M ).

Compensatie versus inkomsten: De vergoeding van Chris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Chris Boerner (54 yo)

2.1yrs

Tenure

US$18,787,618

Compensatie

Dr. Christopher S. Boerner, also known as Chris, Ph.D. served as Chief Operating Officer at Bristol-Myers Squibb Company since April 26, 2023 to 2023 and served as its Executive Vice President since April...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Boerner	CEO & Chairman	2.1yrs	US$18.79m	0.0062% $ 6.2m
David Elkins	Executive VP & CFO	6.1yrs	US$8.71m	0.0082% $ 8.3m
Karin Shanahan	Executive VP	less than a year	US$6.57m	0.00089% $ 891.4k
Greg Meyers	Executive VP and Chief Digital & Technology Officer	3.9yrs	geen gegevens	0.00097% $ 971.5k
Charles Triano	SVP & Head of Investor Relations	no data	geen gegevens	geen gegevens
Kimberly Jablonski	Chief Compliance & Ethics Officer	2.2yrs	geen gegevens	geen gegevens
Cari Gallman	Executive Vice President	less than a year	geen gegevens	0.00054% $ 540.9k
Ahn Poole	Executive VP & Chief People Officer	1.9yrs	geen gegevens	0.00026% $ 260.4k
Joseph Eiden	Head of Medical Affairs	no data	geen gegevens	geen gegevens
Adam Lenkowsky	Executive VP & Chief Commercialization Officer	no data	geen gegevens	0.0012% $ 1.2m
Wendy Bartie	Executive Vice President of Corporate Affairs	3.9yrs	geen gegevens	0.00028% $ 280.4k
Robert Plenge	Executive VP & Chief Research Officer	2.4yrs	geen gegevens	0.00089% $ 891.4k

2.2yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0R1F wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Boerner	CEO & Chairman	2.9yrs	US$18.79m	0.0062% $ 6.2m
Derica Rice	Independent Director	5.3yrs	US$390.00k	geen gegevens
Phyllis Yale	Independent Director	6.1yrs	US$380.00k	geen gegevens
Manuel Hidalgo Medina	Independent Director	4.5yrs	US$350.00k	geen gegevens
Peter Arduini	Independent Director	9.7yrs	US$376.79k	geen gegevens
Deepak Bhatt	Independent Director	3.5yrs	US$350.00k	geen gegevens
Theodore Samuels	Lead Independent Director	8.8yrs	US$440.00k	0.0017% $ 1.7m
Paula Price	Independent Director	5.3yrs	US$380.00k	geen gegevens
Julia Haller	Independent Director	6.1yrs	US$390.00k	0.00067% $ 671.1k
Michael McMullen	Independent director	1.4yrs	US$185.86k	geen gegevens
Karen Vousden	Independent Director	7.9yrs	US$350.00k	geen gegevens

5.3yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0R1F wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/12/01 19:39
Aandelenkoers aan het einde van de dag	2025/12/01 00:00
Inkomsten	2025/09/30
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Bristol-Myers Squibb Company wordt gevolgd door 44 analisten. 26 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
David Toung	Argus Research Company
Charles Butler	Barclays
Luisa Hector	Berenberg

Bristol-Myers Squibb Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Bristol Myers Squibb Announces Management Changes

Bristol Myers Squibb Announces Executive Changes

Bristol-Myers Squibb Company, Annual General Meeting, May 06, 2025

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Recent updates

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

State of Texas Sues Bristol-Myers Squibb and Sanofi for Deceptive Marketing of Blood Thinner Plavix

Bristol Myers Squibb in Collaboration with Johnson & Johnson Announces Update on Phase 3 Librexia ACS Trial

Third quarter 2025 earnings released: EPS: US$1.08 (vs US$0.60 in 3Q 2024)

Bristol-Myers Squibb Company Updates Earnings Guidance for the Year 2025

New major risk - Revenue and earnings growth

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (Deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

Systimmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-Bren, an EGFR X HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors At ESMO 2025

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Orbital Therapeutics, Inc. for $1.5 billion.

Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease

Bristol Myers Squibb Builds on Eliquis (apixaban) Direct-To-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu (deucravacitinib)

Bristol-Myers Squibb Company Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb Company to Report Q3, 2025 Results on Oct 30, 2025

Second quarter dividend of US$0.62 announced

Bristol-Myers Squibb Company Announces Quarterly Dividend, Payable on November 3, 2025

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (Mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

Systimmune Inc. and Bristol Myers Squibb Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation to Systimmune Inc

Bristol Myers Squibb's Application for Breyanzi (Lisocabtagene Maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Second quarter 2025 earnings released: EPS: US$0.64 (vs US$0.83 in 2Q 2024)

Bristol Myers Squibb Announces Management Changes

Bristol Myers Squibb's Supplemental New Drug Application for Sotyktu (Deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 1000 Defensive Index

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of RemS Programs Within Bristol Myers Squibb's Cell Therapy Labels

First quarter dividend of US$0.62 announced

Bristol-Myers Squibb Company Announces Quarterly Dividend, Payable on August 1, 2025

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA -1 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo®? (nivolumab) Across Multiple Solid Tumor Indications

Bristol Myers Squibb to Present Data at ASCO 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo®? (Nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with Pd-1 Expression 1%

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of 2seventy bio, Inc. (NasdaqGS:TSVT).

Bristol Myers Squibb Announces Executive Changes

First quarter 2025 earnings released: EPS: US$1.21 (vs US$5.89 loss in 1Q 2024)

Bristol-Myers Squibb Company Revises Earnings Guidance for the Year 2025

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

Bristol Myers Squibb Announces U.S. Food and Drug Administration Updates CAMZYOS®? (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Opdivo (nivolumab) Plus Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

U.S. Food and Drug Administration Approves Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) as Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications

Us Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights

Upcoming dividend of US$0.62 per share

Bristol-Myers Squibb Company, Annual General Meeting, May 06, 2025

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of Car T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company to Report Q1, 2025 Results on Apr 24, 2025

Bristol-Myers Squibb Company (NYSE:BMY) agreed to acquire 2seventy bio, Inc. (NasdaqGS:TSVT) for approximately $280 million.

Fourth quarter dividend of US$0.62 announced

Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval for Opdivo®? (Nivolumab) Plus Yervoy®? (Ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Bristol-Myers Squibb Company Announces Quarterly Dividend on Common Stock, Payable on May 1, 2025

Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company Provides Update on Phase 3 Relativity-098 Trial

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi (Lisocabtagene Maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Full year 2024 earnings released: US$4.41 loss per share (vs US$3.88 profit in FY 2023)

Bristol Myers Squibb Receives Positive Chmp Opinion for Car T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Presents Results from Checkmate -8Hw Analysis Evaluating Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) Compared to Opdivo Monotherap

Bristol Myers Squibb Announces FDA Approval of Cobenfy

Upcoming dividend of US$0.62 per share

Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Opdivo Qvantig™? (nivolumab and Hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo®? (Nivolumor Opdivo) Indications

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb Company to Report Q4, 2024 Results on Feb 06, 2025

Third quarter dividend increased to US$0.62

Bristol Myers Squibb Company Declares Quarterly Dividend, Payable on February 3, 2025

Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio At Ash 2024 with Long-Term Survival Data and Results from Expanding Pipeline

Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors

Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024

Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024

Third quarter 2024 earnings released: EPS: US$0.60 (vs US$0.94 in 3Q 2023)

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024